186 related articles for article (PubMed ID: 31980915)
1. Treatment with an immature dendritic cell-targeting vaccine supplemented with IFN-α and an inhibitor of DNA methylation markedly enhances survival in a murine melanoma model.
Gordy JT; Luo K; Kapoor A; Kim ES; Ayeh SK; Karakousis PC; Markham RB
Cancer Immunol Immunother; 2020 Apr; 69(4):569-580. PubMed ID: 31980915
[TBL] [Abstract][Full Text] [Related]
2. IFNα and 5-Aza-2'-deoxycytidine combined with a dendritic-cell targeting DNA vaccine alter tumor immune cell infiltration in the B16F10 melanoma model.
Gordy JT; Sandhu AK; Fessler K; Luo K; Kapoor AR; Ayeh SK; Hui Y; Schill C; Chen F; Wang T; Karanika S; Sunshine JC; Karakousis PC; Markham RB
Front Immunol; 2022; 13():1074644. PubMed ID: 36741387
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3α-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons.
Gordy JT; Luo K; Francica B; Drake C; Markham RB
J Immunother; 2018 May; 41(4):181-189. PubMed ID: 29334492
[TBL] [Abstract][Full Text] [Related]
4. Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model.
Gordy JT; Luo K; Zhang H; Biragyn A; Markham RB
J Immunother Cancer; 2016; 4():96. PubMed ID: 28018602
[TBL] [Abstract][Full Text] [Related]
5. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy.
Llopiz D; Ruiz M; Silva L; Repáraz D; Aparicio B; Egea J; Lasarte JJ; Redin E; Calvo A; Angel M; Berzofsky JA; Stroncek D; Sarobe P
Cancer Lett; 2021 Feb; 499():279-289. PubMed ID: 33232788
[TBL] [Abstract][Full Text] [Related]
7. Conditioning vaccination site with irradiated MIP-3alpha-transfected tumor cells enhances efficacy of dendritic cell-based cancer vaccine.
Shih NY; Yang HY; Cheng HT; Hung YM; Yao YC; Zhu YH; Wu YC; Liu KJ
J Immunother; 2009 May; 32(4):363-9. PubMed ID: 19342969
[TBL] [Abstract][Full Text] [Related]
8. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
[TBL] [Abstract][Full Text] [Related]
9. Combination of a MIP3α-antigen fusion therapeutic DNA vaccine with treatments of IFNα and 5-Aza-2'Deoxycytidine enhances activated effector CD8+ T cells expressing CD11c in the B16F10 melanoma model.
Fessler K; Gordy JT; Sandhu AK; Hui Y; Kapoor AR; Ayeh SK; Karanika S; Karakousis PC; Markham RB
Res Sq; 2023 Aug; ():. PubMed ID: 37645859
[TBL] [Abstract][Full Text] [Related]
10. A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth.
Gleisner MA; Pereda C; Tittarelli A; Navarrete M; Fuentes C; Ávalos I; Tempio F; Araya JP; Becker MI; González FE; López MN; Salazar-Onfray F
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690772
[TBL] [Abstract][Full Text] [Related]
11. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
12. Neutrophils produce biologically active macrophage inflammatory protein-3alpha (MIP-3alpha)/CCL20 and MIP-3beta/CCL19.
Scapini P; Laudanna C; Pinardi C; Allavena P; Mantovani A; Sozzani S; Cassatella MA
Eur J Immunol; 2001 Jul; 31(7):1981-8. PubMed ID: 11449350
[TBL] [Abstract][Full Text] [Related]
13. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
[TBL] [Abstract][Full Text] [Related]
14. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
[TBL] [Abstract][Full Text] [Related]
15. MIP-3alpha and MIP-1alpha rapidly mobilize dendritic cell precursors into the peripheral blood.
He S; Cao Q; Yoneyama H; Ge H; Zhang Y; Zhang Y
J Leukoc Biol; 2008 Dec; 84(6):1549-56. PubMed ID: 18791167
[TBL] [Abstract][Full Text] [Related]
16. Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors.
Rettman P; Blunt MD; Fulton RJ; Vallejo AF; Bastidas-Legarda LY; España-Serrano L; Polak ME; Al-Shamkhani A; Retiere C; Khakoo SI
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016721
[TBL] [Abstract][Full Text] [Related]
17. Comparison of fusion protein and DC vaccine in inhibition of mouse B16F10 melanoma tumor.
Zhang Y; Liu X; Wang R; Liu S; Wang Y; Jing L; Louis MDJ; Cao R
Biomed Pharmacother; 2018 Jan; 97():784-792. PubMed ID: 29112931
[TBL] [Abstract][Full Text] [Related]
18. A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.
Gupta S; Termini JM; Rivas Y; Otero M; Raffa FN; Bhat V; Farooq A; Stone GW
Vaccine; 2015 Sep; 33(38):4798-806. PubMed ID: 26241951
[TBL] [Abstract][Full Text] [Related]
19. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.
Wilgenhof S; Van Nuffel AM; Corthals J; Heirman C; Tuyaerts S; Benteyn D; De Coninck A; Van Riet I; Verfaillie G; Vandeloo J; Bonehill A; Thielemans K; Neyns B
J Immunother; 2011 Jun; 34(5):448-56. PubMed ID: 21577140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
